Healthcare Sep 27, 2021 11:57 AM (GMT+8) · EqualOcean
Today, triarm therapeutics limited, an enterprise focusing on innovative cellular immunotherapy products, announced that it had completed three phases of financing in round a, with a total financing amount of US $60 million. Round a investment is strongly supported by panacea venture, VI venture, HT capital, efung capital, Lo co investment fund, Jinpu health fund, Ruifu medical health fund and other international investment companies. Triarm was founded in 2019 by panacea venture. At present, the company has R & D entity branches in Shanghai, Taipei and Reagan sburg, Germany, focusing on the clinical transformation of innovative cellular immunotherapy products, and is committed to providing the next generation of cellular therapy products for cancer patients.